HighTide Therapeutics, Inc.

SEHK:2511 Stock Report

Market Cap: HK$1.6b

HighTide Therapeutics Management

Management criteria checks 2/4

HighTide Therapeutics' CEO is Liping Liu, appointed in Feb 2018, has a tenure of 7.75 years. total yearly compensation is CN¥11.43M, comprised of 25.5% salary and 74.5% bonuses, including company stock and options. directly owns 1.31% of the company’s shares, worth HK$20.88M. The average tenure of the management team and the board of directors is 3.9 years and 2.8 years respectively.

Key information

Liping Liu

Chief executive officer

CN¥11.4m

Total compensation

CEO salary percentage25.49%
CEO tenure7.8yrs
CEO ownership1.3%
Management average tenure3.9yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Here's Why We're Watching HighTide Therapeutics' (HKG:2511) Cash Burn Situation

Jan 20
Here's Why We're Watching HighTide Therapeutics' (HKG:2511) Cash Burn Situation

We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Oct 05
We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

Jun 21
Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Liping Liu's remuneration changed compared to HighTide Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-CN¥291m

Mar 31 2025n/an/a

-CN¥336m

Dec 31 2024CN¥11mCN¥3m

-CN¥382m

Sep 30 2024n/an/a

-CN¥491m

Jun 30 2024n/an/a

-CN¥601m

Mar 31 2024n/an/a

-CN¥770m

Dec 31 2023CN¥15mCN¥4m

-CN¥939m

Sep 30 2023n/an/a

-CN¥803m

Jun 30 2023n/an/a

-CN¥666m

Mar 31 2023n/an/a

-CN¥428m

Dec 31 2022CN¥7mCN¥4m

-CN¥190m

Dec 31 2021CN¥7mCN¥3m

-CN¥221m

Compensation vs Market: Liping's total compensation ($USD1.62M) is above average for companies of similar size in the Hong Kong market ($USD328.34K).

Compensation vs Earnings: Liping's compensation has been consistent with company performance over the past year.

CEO

Liping Liu (55 yo)

7.8yrs
Tenure
CN¥11,430,000
Compensation

Dr. Liping Liu has been the Chief Executive Officer and Executive Director of HighTide Therapeutics, Inc. since February 28, 2018 and its chairwoman since December 22, 2023 She has been the Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Liping Liu
CEO & Chairwoman7.8yrsCN¥11.43m1.31%
HK$ 20.9m
Meng Yu
Deputy GM & Executive Director8.4yrsCN¥11.83m0.57%
HK$ 9.1m
Koon Yin Sim
Chief Financial Officer2.9yrsno datano data
Liping Gao
Joint Company Secretary & Investor Relations Director3.1yrsno datano data
Leigh Anne MacConell
Chief Development Officer4.8yrsno datano data
Pik Man Chu
Joint Company Secretary1.9yrsno datano data
3.9yrs
Average Tenure
49.5yo
Average Age

Experienced Management: 2511's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Liping Liu
CEO & Chairwoman7.8yrsCN¥11.43m1.31%
HK$ 20.9m
Meng Yu
Deputy GM & Executive Director2.5yrsCN¥11.83m0.57%
HK$ 9.1m
Gwen A. Melincoff
Member of the Scientific Advisory Boardno datano datano data
Bo Tan
Independent Non-Executive Director1.9yrsCN¥184.00kno data
Lawrence Goldkind
Member of Scientific Advisory Boardno datano datano data
Xun Zhu
Non-Executive Director5yrsCN¥1.29m0.21%
HK$ 3.3m
Li Jin
Independent Non-Executive Director1.9yrsCN¥184.00kno data
Kris Kowdley
Member of Scientific Advisory Boardno datano datano data
Feng Jiang
Non-Executive Director3yrsno datano data
Lixiong Ma
Deputy Chairman of the Board4yrsCN¥12.23m0.43%
HK$ 6.9m
Tak Wai Hung
Independent Non-Executive Director1.9yrsCN¥184.00kno data
Adrian M. Di Bisceglie
Member of Scientific Advisory Boardno datano datano data
2.8yrs
Average Tenure
55yo
Average Age

Experienced Board: 2511's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/30 05:45
End of Day Share Price 2025/11/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HighTide Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.